Literature DB >> 33028580

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.

Dana E Orange1,2, Jessica K Gordon1, Kimberly Showalter3, Robert Spiera1, Cynthia Magro4, Phaedra Agius5, Viktor Martyanov6,7, Jennifer M Franks6,7, Roshan Sharma5, Heather Geiger5, Tammara A Wood6,7, Yaxia Zhang8, Caryn R Hale2, Jackie Finik9, Michael L Whitfield6,7.   

Abstract

OBJECTIVE: We sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma).
METHODS: Fifty-eight forearm biopsies were evaluated from 26 individuals with dcSSc in two clinical trials. Histologic/immunophenotypic assessments of global severity, alpha-smooth muscle actin (aSMA), CD34, collagen, inflammatory infiltrate, follicles and thickness were compared with gene expression and clinical data. Support vector machine learning was performed using scleroderma gene expression subset (normal-like, fibroproliferative, inflammatory) as classifiers and histology scores as inputs. Comparison of w-vector mean absolute weights was used to identify histologic features most predictive of gene expression subset. We then tested for differential gene expression according to histologic severity and compared those with clinical improvement (according to the Combined Response Index in Systemic Sclerosis).
RESULTS: aSMA was highest and CD34 lowest in samples with highest local Modified Rodnan Skin Score. CD34 and aSMA changed significantly from baseline to 52 weeks in clinical improvers. CD34 and aSMA were the strongest predictors of gene expression subset, with highest CD34 staining in the normal-like subset (p<0.001) and highest aSMA staining in the inflammatory subset (p=0.016). Analysis of gene expression according to CD34 and aSMA binarised scores identified a 47-gene fibroblast polarisation signature that decreases over time only in improvers (vs non-improvers). Pathway analysis of these genes identified gene expression signatures of inflammatory fibroblasts.
CONCLUSION: CD34 and aSMA stains describe distinct fibroblast polarisation states, are associated with gene expression subsets and clinical assessments, and may be useful biomarkers of clinical severity and improvement in dcSSc. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  autoimmune diseases; fibroblasts; inflammation; scleroderma; systemic

Mesh:

Substances:

Year:  2020        PMID: 33028580      PMCID: PMC8600653          DOI: 10.1136/annrheumdis-2020-217840

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  CD34 stromal expression is inversely proportional to smooth muscle actin expression and extent of morphea.

Authors:  J S Lee; H S Park; H S Yoon; J H Chung; S Cho
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-07-06       Impact factor: 6.166

Review 2.  Clinical Trial Design Issues in Systemic Sclerosis: an Update.

Authors:  Jessica K Gordon; Robyn T Domsic
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

3.  Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.

Authors:  Shane Lofgren; Monique Hinchcliff; Mary Carns; Tammara Wood; Kathleen Aren; Esperanza Arroyo; Peggie Cheung; Alex Kuo; Antonia Valenzuela; Anna Haemel; Paul J Wolters; Jessica Gordon; Robert Spiera; Shervin Assassi; Francesco Boin; Lorinda Chung; David Fiorentino; Paul J Utz; Michael L Whitfield; Purvesh Khatri
Journal:  JCI Insight       Date:  2016-12-22

4.  The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.

Authors:  D E Furst; P J Clements; V D Steen; T A Medsger; A T Masi; W A D'Angelo; P A Lachenbruch; R G Grau; J R Seibold
Journal:  J Rheumatol       Date:  1998-01       Impact factor: 4.666

5.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

Review 6.  Transforming growth factor beta as a therapeutic target in systemic sclerosis.

Authors:  John Varga; Boris Pasche
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

7.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

Authors:  P Clements; P Lachenbruch; J Siebold; B White; S Weiner; R Martin; A Weinstein; M Weisman; M Mayes; D Collier
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

Review 8.  Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.

Authors:  Viktor Martyanov; Michael L Whitfield
Journal:  Curr Opin Rheumatol       Date:  2016-01       Impact factor: 5.006

9.  Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis.

Authors:  Pravitt Gourh; Frank C Arnett; Filemon K Tan; Shervin Assassi; Dipal Divecha; Gene Paz; Terry McNearney; Hilda Draeger; John D Reveille; Maureen D Mayes; Sandeep K Agarwal
Journal:  Ann Rheum Dis       Date:  2009-09-23       Impact factor: 19.103

10.  Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.

Authors:  Jessica K Gordon; Viktor Martyanov; Cynthia Magro; Horatio F Wildman; Tammara A Wood; Wei-Ti Huang; Mary K Crow; Michael L Whitfield; Robert F Spiera
Journal:  Arthritis Res Ther       Date:  2015-08-18       Impact factor: 5.156

View more
  8 in total

1.  Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.

Authors:  Brian Skaug; Marka A Lyons; William R Swindell; Gloria A Salazar; Minghua Wu; Tuan M Tran; Julio Charles; Connor P Vershel; Maureen D Mayes; Shervin Assassi
Journal:  Ann Rheum Dis       Date:  2021-12-22       Impact factor: 19.103

Review 2.  Wound healing, fibroblast heterogeneity, and fibrosis.

Authors:  Heather E Talbott; Shamik Mascharak; Michelle Griffin; Derrick C Wan; Michael T Longaker
Journal:  Cell Stem Cell       Date:  2022-08-04       Impact factor: 25.269

3.  Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study.

Authors:  Aurélien Chepy; Solange Vivier; Fabrice Bray; Camille Ternynck; Jean-Pascal Meneboo; Martin Figeac; Alexandre Filiot; Lucile Guilbert; Manel Jendoubi; Christian Rolando; David Launay; Sylvain Dubucquoi; Guillemette Marot; Vincent Sobanski
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

4.  Feature Subset Selection with Optimal Adaptive Neuro-Fuzzy Systems for Bioinformatics Gene Expression Classification.

Authors:  Anwer Mustafa Hilal; Areej A Malibari; Marwa Obayya; Jaber S Alzahrani; Mohammad Alamgeer; Abdullah Mohamed; Abdelwahed Motwakel; Ishfaq Yaseen; Manar Ahmed Hamza; Abu Sarwar Zamani
Journal:  Comput Intell Neurosci       Date:  2022-05-14

Review 5.  Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need.

Authors:  Ariane L Herrick; Shervin Assassi; Christopher P Denton
Journal:  Nat Rev Rheumatol       Date:  2022-03-15       Impact factor: 32.286

Review 6.  [Social media-Chances and risks for rheumatology].

Authors:  I Haase; J Mucke; D Vossen; J Knitza; N Ruffer; M Zeeck; M Krusche
Journal:  Z Rheumatol       Date:  2022-04-08       Impact factor: 1.372

Review 7.  The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review.

Authors:  Francesco Bonomi; Silvia Peretti; Gemma Lepri; Vincenzo Venerito; Edda Russo; Cosimo Bruni; Florenzo Iannone; Sabina Tangaro; Amedeo Amedei; Serena Guiducci; Marco Matucci Cerinic; Silvia Bellando Randone
Journal:  J Pers Med       Date:  2022-07-23

8.  Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis.

Authors:  Heng Li; Liping Ding; Xiaoping Hong; Yulan Chen; Rui Liao; Tingting Wang; Shuhui Meng; Zhenyou Jiang; Dongzhou Liu
Journal:  BMC Cancer       Date:  2021-03-10       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.